RESUMEN
Two HPLC methods for determination of tetroxoprim and sulphadiazine in pharmaceutical dosage forms and in biological fluid are reported. Both methods show good linearity, precision, accuracy and reproducibility. The serum levels and urinary excretion of tetroxoprim and sulphadiazine in man, after oral administration of two different syrup formulations, are reported. Tetroxoprim embonate, an insoluble salt very useful for obtaining a suspension with good palatability, shows a bioavailability not statistically different from that of tetroxoprim base. Sulphadiazine shows the same bioavailability in the two syrups.
Asunto(s)
Antiinfecciosos/análisis , Pirimidinas/análisis , Sulfadiazina/análisis , Antiinfecciosos/sangre , Antiinfecciosos/orina , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Humanos , Masculino , Pirimidinas/sangre , Pirimidinas/orina , Espectrofotometría Ultravioleta , Sulfadiazina/sangre , Sulfadiazina/orinaAsunto(s)
Antraquinonas/análisis , NADH NADPH Oxidorreductasas/antagonistas & inhibidores , Administración Oral , Animales , Antraquinonas/sangre , Antraquinonas/orina , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Indicadores y Reactivos , Masculino , Ratas , Ratas EndogámicasRESUMEN
A new antitumor agent having the chemical composition of 3-(p-fluorophenyl)-Lalanyl-3-[m-bis-(2-chloroethyl)aminophenyl]-L- alanyl-L-methionine ethyl ester hydrochloride (PTT 119) was synthetized. It fundamental toxicological data in mice and rats were assessed; its antitumor activity was investigated by establishing in mice, inoculated with L 1210 leukemia or in AKR mice with spontaneous leukemia of viral origin, a significant increase in Mean Survival Time as well as a percent increase of Increased Life Span and of the number of survivors.